Presented a program capable of detecting neurodegeneration biomarkers through magnetic

October 08, 2020

Magnetic resonance imaging is the most sensitive and reliable technique for diagnosing and monitoring neurodegenerative diseases. Through the images obtained, we can make a complete anatomical analysis of the brain and detect atrophy in specific regions. However, the inspection of the images is usually visual, which means that certain signs of neurodegeneration, invisible to the human eye, are not detected until the damage is already advanced.

Dr. Estela Cámara from Bellvitge Biomedical Research Institute (IDIBELL) and Psychology Faculty and the Neuroscience Institute of the University of Barcelona (UBNeuro), together with Alicia Palomar, has designed a computer program that allows the quantitative analysis of magnetic resonance images easily, quickly and adaptable to any brain affection. This program, called SeSBAT (Single Subject Brain Analysis Toolbox), integrates different image analysis protocols that can measure the volume of specific regions of the brain or perform a general exploration of it, being able to detect small changes, invisible to the eye, but that could predict the risk of developing a degenerative disease.

SeSBAT opens the door to the identification of new biomarkers that would help to improve the early detection and monitoring of neurodegenerative diseases. Since it is a quantitative analysis, it is capable of identifying anatomical modifications of the brain that take place before the appearance of symptoms.

With this type of integrated analysis, data can be extracted from a single individual, avoiding the inter-individual variability of working with groups. This allows the individualized monitoring of a patient over time, which would be very useful to determine the efficacy of certain drugs in clinical trials or to monitor people at risk of developing a neurodegenerative disease.

Dr. Cámara's team has tested the accuracy of this new tool in magnetic resonance imaging of patients with Huntington's neurodegenerative disease. The results, published in the journal Frontiers in Systems Neuroscience, show how this tool is able to identify those patients who are in the early stages of the disease, and even those who have not yet presented the first symptoms.

Dr. Cámara states that it is a very versatile program that could be adapted and personalized for each type of neurodegenerative disease or project. The Cámara's group opens the doors to new collaborations with groups interested in applying this technology to their projects. Similarly, a tool like this could easily be applied to routine clinical practice, allowing a much deeper analysis of MRI images and more accurate management of patients with neurodegenerative diseases.
-end-


IDIBELL-Bellvitge Biomedical Research Institute

Related Neurodegenerative Diseases Articles from Brightsurf:

Bringing drugs to the brain with nanoparticles to treat neurodegenerative diseases
Researchers from the Institut national de la recherche scientifique (INRS) have shown that nanoparticles could be used to deliver drugs to the brain to treat neurodegenerative diseases.

First 'pathoconnectome' could point toward new treatments for neurodegenerative diseases
Scientists from the John A. Moran Eye Center at the University of Utah have achieved another first in the field of connectomics, which studies the synaptic connections between neurons.

Unlocking the mystery of tau for treatment of neurodegenerative diseases
A team of researchers from various collaborating universities and hospitals in Japan has uncovered crucial molecular details regarding the activity of the ''tau'' protein, promising to revolutionize the therapy of tau-induced neurodegenerative diseases.

Investigational drug stops toxic proteins tied to neurodegenerative diseases
An investigational drug that targets an instigator of the TDP-43 protein, a well-known hallmark of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), may reduce the protein's buildup and neurological decline associated with these disorders, suggests a pre-clinical study from researchers at Penn Medicine and Mayo Clinic.

Inhibition of sphingolipid metabolism and neurodegenerative diseases
Disrupting the production of a class of lipids known as sphingolipids in neurons improved symptoms of neurodegeneration and increased survival in a mouse model.

How understanding the dynamics of yeast prions can shed light on neurodegenerative diseases
How understanding the dynamics of yeast prions can shed light on neurodegenerative diseases

New family of molecules to join altered receptors in neurodegenerative diseases
An article published in the Journal of Medicinal Chemistry shows a new family of molecules with high affinity to join imidazoline receptors, which are altered in the brain of those patients with neurodegenerative diseases such as Alzheimer's, Parkinson's and Huntington's.

Examining diagnoses of stress-related disorders, risk of neurodegenerative diseases
Researchers investigated how stress-related disorders (such as posttraumatic stress disorder, adjustment disorder and stress reactions) were associated with risk for neurodegenerative diseases, including Alzheimer and Parkinson disease and amyotrophic lateral sclerosis (ALS), using data from national health registers in Sweden.

Toxic protein, linked to Alzheimer's and neurodegenerative diseases, exposed in new detail
The protein tau has long been implicated in Alzheimer's and a host of other debilitating brain diseases.

Study uncovers unexpected connection between gliomas, neurodegenerative diseases
New basic science and clinical research identifies TAU, the same protein studied in the development of Alzheimer's, as a biomarker for glioma development.

Read More: Neurodegenerative Diseases News and Neurodegenerative Diseases Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.